SCHEMBL420104

SCHEMBL420104

Cn1cc2ccc(Br)cc2n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.61
KDM4E B2RXH2 2/20 0.61
ALDH1A1 P00352 2/20 0.61
NSD2 O96028 1/20 0.61
BACE1 P56817 2/20 0.42
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
HTT P42858 1/20 0.41
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
TP53 P04637 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NOTUM Q6P988 1/20 0.36
PABPC1 P11940 1/20 0.36
KIT P10721 1/20 0.36
PDGFRA P16234 1/20 0.36
KDR P35968 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL906617 0.84 KDM4E (0.49) MAPTKDM4EALDH1A1NSD2BACE1
SCHEMBL422734 0.78 MAPT (0.63) MAPTKDM4EALDH1A1NSD2BACE1
SCHEMBL22946632 0.76 KDM4E (0.61) MAPTKDM4EALDH1A1NSD2BACE1
SCHEMBL22737499 0.76 KDM4E (0.61) MAPTKDM4EALDH1A1NSD2NPC1
SCHEMBL22946640 0.76 KDM4E (0.61) MAPTKDM4EALDH1A1NSD2CYP1A2
SCHEMBL17794415 0.76 MAPT (0.61) MAPTKDM4EALDH1A1NSD2NOTUM
SCHEMBL1489105 0.76 KDM4E (1.00) MAPTKDM4EALDH1A1NSD2HTT
SCHEMBL14077301 0.76 NPC1 (0.53) MAPTKDM4EALDH1A1NSD2HTT
SCHEMBL25153641 0.76 NOTUM (0.41) MAPTKDM4EALDH1A1NSD2BACE1
SCHEMBL16595800 0.76 NOTUM (0.40) MAPTKDM4EALDH1A1NSD2BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122071464-A Heterocyclic compound, pharmaceutical composition thereof and application thereof 上海璎黎药业有限公司 2026-05-22 CN disclosed
US-12612379-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2026-04-28 US disclosed
US-12522595-B2 Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2026-01-13 US disclosed
US-12447153-B2 HER2 mutation inhibitors PFIZER INC. (US) 2025-10-21 US disclosed
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
US-20250152564-A1 PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-05-15 US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
CN-118574831-A Biological inhibitor containing acrylketone, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-08-30 CN disclosed
CN-109988144-B Aromatic vinyl or aromatic ethyl derivative, preparation method, intermediate, pharmaceutical composition and application thereof 广州再极医药科技有限公司 2024-07-05 CN disclosed
CN-117986262-A Condensed bicyclic compounds, preparation method and application thereof in medicine 江苏恒瑞医药股份有限公司 2024-05-07 CN disclosed
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHAMA CORPORATION (JP) 2007-09-13 US disclosed
CN-101031539-A Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHAMA CORP (JP) 2007-09-05 CN disclosed
US-20070197564-A1 Compounds for the treatment of inflammatory disorders SCHERING CORPORATION 2007-08-23 US disclosed
US-20070197564-A1 Compounds for the treatment of inflammatory disorders SCHERING CORPORATION 2007-08-23 US disclosed
US-20070197564-A1 Compounds for the treatment of inflammatory disorders SCHERING CORPORATION 2007-08-23 US disclosed
WO-2007084451-A1 HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION (US) 2007-07-26 WO disclosed
CN-1653032-A Substituted phenylalkanoic acid derivatives and use thereof ASAHI CHEMICAL IND (JP) 2005-08-10 CN disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612379-B2 Inhibitors of APOL1 and methods of using same APOL1, RNASE1, LOXL1 MAPT 1838/4885KDM4E 4748/4885ALDH1A1 3134/4885
US-20250152564-A1 PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF CYP51A1, HSD17B7, CYP46A1 MAPT 4016/4885KDM4E 2241/4885ALDH1A1 522/4885
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN MAPT 2959/4885KDM4E 1882/4885ALDH1A1 79/4885
US-20070197564-A1 Compounds for the treatment of inflammatory disorders ADAMTS1, ADAMTS13, ADAMTS7 MAPT 622/4885KDM4E 4550/4885ALDH1A1 1372/4885
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 MAPT 4799/4885KDM4E 2361/4885ALDH1A1 409/4885
US-12447153-B2 HER2 mutation inhibitors ERBB2, EGFR, ERBB3 MAPT 2119/4885KDM4E 2849/4885ALDH1A1 2320/4885
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 MAPT 4869/4885KDM4E 1472/4885ALDH1A1 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.